Background
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide first isolated from human plasma by Pickart in 1973. It is found in plasma at approximately 200 ng/mL in young adults but declines with aging. GHK-Cu has been studied for decades for its role in wound healing, skin regeneration, and anti-aging.
Pickart, the original discoverer of GHK-Cu, provides a comprehensive synthesis of the evidence in this review.
Methods
Narrative review of in vitro, animal, and limited human studies conducted from 1973–2012 on GHK-Cu biology. Gene expression analysis using microarray data from GHK-treated cell lines.
Key Findings
Wound healing and tissue remodeling:
- Stimulates synthesis of collagen types I, III, IV, V, VI, VII, XII, XIII, XIV and XVII
- Increases fibronectin, laminin, and proteoglycans
- Stimulates angiogenesis via VEGF upregulation
- Activates wound contraction fibroblasts (wound myofibroblasts)
Anti-inflammatory and antioxidant effects:
- Reduces TNF-α, IL-6, and IL-1β in wound models
- Scavenges reactive oxygen species
- Upregulates superoxide dismutase (SOD) and catalase
Gene expression (microarray):
- Modulates expression of 4,058 genes in dermal fibroblasts
- Resets gene expression patterns toward a younger cellular phenotype
- Downregulates oncogenic pathways
Skin-specific human data:
- Multiple small-sample RCTs demonstrating reduced fine lines, improved elasticity, and increased skin density with topical GHK-Cu formulations
- Enhanced efficacy compared to retinoic acid in split-face studies (N=20–40)
Clinical Significance
GHK-Cu represents a well-characterized, naturally derived peptide with a broad mechanism of action in tissue repair. Its topical safety has been established in cosmetic products for decades. The anti-aging skin evidence — while from small studies — is consistent and supported by robust cell culture mechanistic data.
The gene expression data suggesting “re-programming” to a younger phenotype is preliminary but biologically interesting.
Limitations
- Most human clinical data from small split-face cosmetic studies
- Injectable/systemic human data essentially absent
- Reviewer (Pickart) is original discoverer and has commercial interests in GHK-Cu
- Gene expression data requires validation with functional outcomes